Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
Adolescent
Antineoplastic Agents
/ adverse effects
Busulfan
/ adverse effects
Child
Child, Preschool
Cyclophosphamide
/ therapeutic use
Disease-Free Survival
Female
Hematologic Neoplasms
/ therapy
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Infant
Male
Myeloablative Agonists
/ adverse effects
Retrospective Studies
Transplantation Conditioning
/ adverse effects
Transplantation, Homologous
Treatment Outcome
Whole-Body Irradiation
/ methods
Allogeneic stem cell transplantation
conditioning regimen
pediatric
treosulfan
Journal
Pediatric hematology and oncology
ISSN: 1521-0669
Titre abrégé: Pediatr Hematol Oncol
Pays: England
ID NLM: 8700164
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
pubmed:
14
3
2020
medline:
13
11
2020
entrez:
14
3
2020
Statut:
ppublish
Résumé
Treosulfan-based regimens constitute a feasible and increasingly used, but still myeloablative, conditioning in pediatric allogeneic hematopoietic stem cell transplantation (HSCT). We retrospectively analyzed the acute toxicity and outcome of all consecutive (2004-2015) pediatric HSCT patients prepared for HSCT with treosulfan in a single-center setting. We included HSCTs performed for both nonmalignant (
Identifiants
pubmed: 32166994
doi: 10.1080/08880018.2020.1738604
doi:
Substances chimiques
Antineoplastic Agents
0
Myeloablative Agonists
0
Cyclophosphamide
8N3DW7272P
treosulfan
CO61ER3EPI
Busulfan
G1LN9045DK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
355-364Commentaires et corrections
Type : CommentIn